公开(公告)号：US20210299126A1

公开(公告)日：2021-09-30

申请号：US17261954

申请日：2019-07-22

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： James Aaron BALOG ,  Jay A. MARKWALDER ,  Weifang SHAN ,  David K. WILLIAMS ,  Susheel Jethanand NARA ,  Saumya ROY ,  Soodamani THANGAVEL ,  Srinivas CHERUKU ,  Ramesh Kumar SISTLA

IPC: A61K31/506 ,  A61K39/395 ,  C07D403/10 ,  C07D403/14 ,  C07D413/10 ,  C07D417/10 ,  C07D213/75 ,  C07D401/14 ,  A61K31/4439 ,  A61K31/4418 ,  A61K31/496 ,  A61K31/501 ,  A61K31/519 ,  C07D405/14 ,  C07D487/04 ,  C07D417/14 ,  A61K31/5377 ,  A61K31/4725 ,  C07D413/14 ,  C07D213/74

Abstract: The present invention provides compounds of formula (I): wherein all of the variables are as defined herein. These compounds are inhibitors of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases.

公开(公告)号：US20210290613A1

公开(公告)日：2021-09-23

申请号：US16328449

申请日：2017-08-25

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Emily Charlotte CHERNEY ,  Weifang SHAN ,  Liping ZHANG ,  Susheel Jethanand NARA ,  Audris HUANG ,  James Aaron BALOG

IPC: A61K31/4709 ,  C07D401/08 ,  C07D491/056 ,  C07D471/04 ,  C07D417/12 ,  C07D401/12 ,  C07D413/12 ,  C07D487/04 ,  A61K31/517 ,  A61K31/5025 ,  A61K31/4375 ,  A61K39/395

Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

公开(公告)号：US20190119216A1

公开(公告)日：2019-04-25

申请号：US16098260

申请日：2017-05-04

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Emily Charlotte CHERNEY ,  Liping ZHANG ,  David K. WILLIAMS ,  James Aaron BALOG

IPC: C07D215/18 ,  C07D401/04 ,  C07D215/233 ,  A61K31/4709 ,  A61K31/47 ,  A61K45/06 ,  A61P35/00

Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.